BSEGeneral2d ago · 13 Oct 2026, 12:18 pm

The Board of Directors of the Company at their Meeting held today i.e., Tuesday, October 13, 2026, has approved the following: 1. Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the Company 2. Re-Appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director of the Company

Senores Pharmaceuticals Ltd · 544319

✦ AI SummaryMgmt Change

The Board of Directors of Senores Pharmaceuticals Ltd has approved the re-appointment of Mr. Swapnil Jatinbhai Shah as the Managing Director and Mr. Chetan Bipinchandra Shah as the Whole Time Director of the Company, both for a period of three consecutive years, subject to shareholder approval.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting

Attachments (1)

📄

029cedcc-4f82-43d9-9325-4fed3563f1ca.pdf

pdf

Download →
View document text
Date: October 13, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Dear Sir/Madam, Sub.: Outcome of Board Meeting of the Company held on Tuesday, October 13, 2026 With reference to the captioned subject, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e., Tuesday, October 13, 2026, has inter-alia, approved the following: 1. Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the Company Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the re-appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the Company, liable to retire by rotation for a period of three (3) consecutive years w.e.f. October 15, 2026 subject to the approval of shareholders to be obtained through postal ballot process. The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- A. 2. Re-Appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director of the Company Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the re-appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director of the Company, liable to retire by rotation for a period of three (3) consecutive years w.e.f. November 10, 2026 subject to the approval of shareholders to be obtained through postal ballot process. The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- B. Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Kindly note that the meeting of Board of Directors of the Company commenced at 11:30 AM (IST) and concluded at 11:55 PM (IST).: This intimation and aforesaid information are also being uploaded on the Company’s website at www.senorespharma.com. You are requested to take the same on record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer ICSI Membership No.: A34516 Enclosures: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Annexure-A Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the Company Sr. Particulars Details 1. Reason for change viz. appointment, Re-Appointment of Mr. Swapnil Jatinbhai Shah re-appointment, resignation, removal, (DIN: 05259821) as the Managing Director of the death or otherwise Company. 2. Date of appointment/re- For a further period of three (3) consecutive years appointment/cessation (as applicable) w.e.f. October 15, 2026 subject to the approval of and term of appointment shareholders to be obtained through postal ballot process. 3. Brief Profile (in case of re- Mr. Swapnil Jatinbhai Shah is the Promoter and appointment) Managing Director of the Company. He has over 15 years of experience in the pharmaceutical sector. He was previously involved in business operations in a Delaware based pharmaceutical company. He is currently leading the Company’s overall functioning and is a part of the core management team. He is also responsible for product portfolio management, corporate strategy, business development and overall strategic management of our Company. He holds a master’s degree in business administration from Hofstra University, New York and a bachelor’s degree in chemical engineering from Nirma University. He was previously associated as a strategist at Planet Payment Inc. (now acquired by Fintrx, Inc., a fintech company listed on the NASDAQ). He is a convenor of the pharma panel in the Confederation of Indian Industry (CII), Gujarat State Council. 4. Disclosure of relationships between Mr. Swapnil Jatinbhai Shah is not related inter-se to directors (in case of re-appointment of any other Directors of Company. a director) 5. Information as required under BSE Mr. Swapnil Jatinbhai Shah is not debarred from circular no. LIST/COMP/14/2018- 19 holding the office of Director by virtue of any SEBI and NSE circular no. order or any other such authority. NSE/CML/2018/24, dated June 20, 2018 Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Annexure-B Re-Appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director of the Company Sr. Particulars Details 1. Reason for change viz. appointment, Re-Appointment of Mr. Chetan Bipinchandra Shah re-appointment, resignation, removal, (DIN: 10381971) as the Whole-time Director of the death or otherwise Company. 2. Date of appointment/re- For a further period of three (3) consecutive years appointment/cessation (as applicable) w.e.f. November 10, 2026 subject to the approval of and term of re-appointment shareholders to be obtained through postal ballot process. 3. Brief Profile (in case of re- Mr. Chetan Bipinchandra Shah is the Whole-Time appointment) Director and Chief Operating Officer of the Company. He has over 30 years of experience of which 25 years of experience is in the pharmaceutical industry and was previously associated with pharmaceutical companies such as Torrent Pharmaceuticals Limited and Cadila Pharmaceuticals Limited. He was also associated with Reliance Retail Limited, Reliance Fresh Limited and Reliance Corporate IT Park Limited. He is a part of the core management team of the Company and is responsible for strategy planning, capital expenditure planning, capacity expansion, policy enforcement, mergers and acquisitions, supply chain for both domestic and international chain, manufacturing processes and automation, risk management and overall management information system. 4. Disclosure of relationships between Mr. Chetan Bipinchandra Shah is not related inter- directors (in case of re-appointment of se to any other Directors of Company. a director) 5. Information as required under BSE Mr. Chetan Bipinchandra Shah is not debarred from circular no. LIST/COMP/14/2018- 19 holding the office of Director by virtue of any SEBI and NSE circular no. order or any other such authority. NSE/CML/2018/24, dated June 20, 2018 Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263